A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

ClinicalTrials.gov ID: NCT06876649

Public ClinicalTrials.gov record NCT06876649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Study identification

NCT ID: NCT06876649
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 787 participants

Conditions and interventions

Conditions

Interventions

Pirtobrutinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 19, 2025
Primary completion: Apr 30, 2030
Completion: Nov 30, 2032
Last update posted: Mar 1, 2026

2025 – 2032

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Cancer Specialists, LLC	Jacksonville	Florida	32256	Not yet recruiting
Sylvester Comprehensive Cancer Center	Miami	Florida	33136-1002	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232-6422	Recruiting
The Emory Clinic	Atlanta	Georgia	30322-1013	Not yet recruiting
Northwestern University	Chicago	Illinois	60611-3013	Not yet recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic- Minnesota	Rochester	Minnesota	55905	Recruiting
University Of Nebraska Medical Center	Omaha	Nebraska	69198	Recruiting
Cayuga Cancer Center	Ithaca	New York	14850	Recruiting
Northwell Health	Lake Success	New York	11042-1118	Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York	New York	New York	10065-6007	Not yet recruiting
Duke University Medical Center	Durham	North Carolina	27710-4000	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210-1063	Recruiting
University of Pennsylvania Hospital	Philadelphia	Pennsylvania	19104	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203-2659	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Swedish Cancer Institute	Seattle	Washington	98104-3588	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226-3548	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06876649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 1, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06876649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →